<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">R Michael Tuttle, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular or C cells of the thyroid gland. MTC accounts for approximately 1 to 2 percent of thyroid cancers in the United States [<a href="#rid1">1</a>]. The production of calcitonin is a characteristic feature of this tumor.</p><p>Most medullary thyroid carcinomas are sporadic. However, approximately 25 percent are familial as part of the multiple endocrine neoplasia type 2 (MEN2) syndrome. The clinical manifestations, diagnosis, evaluation, and clinical staging of MTC will be covered in this topic review. Treatment of this disorder is discussed separately. MEN2 is reviewed in detail elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2190.html" rel="external">"Medullary thyroid cancer: Surgical treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7869.html" rel="external">"Classification and genetics of multiple endocrine neoplasia type 2"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H1589428"><span class="h2">Sporadic MTC</span><span class="headingEndMark"> — </span>Sporadic medullary thyroid cancer (MTC) accounts for approximately 75 percent of all cases of the disease  (<a class="graphic graphic_table graphicRef85653" href="/z/d/graphic/85653.html" rel="external">table 1</a>). The typical age of presentation is in the fourth and sixth decades of life [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms and signs</strong> – The most common presentation of sporadic MTC is that of a solitary thyroid nodule, which occurs in 75 to 95 percent of patients [<a href="#rid2">2-5</a>]. The C cells are predominantly located in the upper portion of each thyroid lobe; thus, most tumors are located in this region. In most patients with MTC, the disease has already metastasized at the time of diagnosis. Approximately 70 percent of patients have clinically detectable cervical lymph node involvement, up to 15 percent have symptoms of upper aerodigestive tract compression or invasion such as dysphagia or hoarseness, and approximately 5 to 10 percent have distant metastatic disease [<a href="#rid1">1,6</a>]. Distant metastases may occur in the liver, lung, bones, and, less often, brain and skin. Nodal metastases are more common in patients with multifocal disease [<a href="#rid7">7</a>]. However, as calcitonin screening results in the identification of more "micro" medullary cancers, the number of patients with metastases at presentation appears to be decreasing [<a href="#rid8">8-10</a>]. Calcitonin screening for MTC in patients with thyroid nodules is controversial. (See <a class="local">'Diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules", section on 'Serum calcitonin concentration'</a>.)</p><p></p><p class="bulletIndent1">Systemic symptoms may occur due to hormonal secretion by the tumor. Tumor secretion of calcitonin, calcitonin gene-related peptide, or other substances can cause diarrhea or facial flushing in patients with advanced disease. In addition, occasional tumors secrete corticotropin (ACTH), causing ectopic Cushing syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biochemical tests</strong> – Basal serum calcitonin concentrations usually correlate with tumor mass but also reflect tumor differentiation, and they are almost always high in patients with a palpable tumor [<a href="#rid6">6</a>]. Most MTCs also secrete carcinoembryonic antigen (CEA), which, like calcitonin, can be used as a tumor marker [<a href="#rid11">11,12</a>]. In addition, the expression of CEA on MTC cells has led to the use of anti-CEA antibodies for immunotherapy. (See  <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">"Medullary thyroid cancer: Systemic therapy and immunotherapy", section on 'Immunotherapy'</a>.)</p><p></p><p class="bulletIndent1">Thyroid function tests are normal in patients with MTC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – There are several ultrasound features of thyroid nodules (eg, hypoechoic, microcalcifications) that are associated with thyroid cancer risk. However, there are no ultrasound features that are pathognomonic for thyroid cancer. Furthermore, the majority of studies evaluating suspicious ultrasound characteristics of nodules focused on papillary thyroid cancer (see  <a class="medical medical_review" href="/z/d/html/7859.html" rel="external">"Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Criteria for identifying cancer'</a>). In a small retrospective study examining the ultrasound characteristic of nodules that were histologically proven to be MTC and papillary thyroid cancer, 50 percent of MTCs were solid and hypoechoic and 16 percent showed microcalcifications, compared with 69.2 and 69.2 percent, respectively, for papillary thyroid cancers [<a href="#rid13">13</a>]. The presence of at least one suspicious ultrasound feature was almost equal in patients with MTC (58.3 percent) and controls with benign nodules (55.5 percent), whereas it was significantly more frequent in patients with papillary thyroid cancer (100 percent). In other series, hypoechogenicity was present in 50 to 89 percent and microcalcifications in 30 to 70 percent [<a href="#rid14">14-16</a>], and there was no difference in echogenicity or the presence or type of calcifications between MTC and papillary thyroid cancer [<a href="#rid15">15,16</a>]. Large areas of calcification (macrocalcification) were noted in 16 to 30 percent [<a href="#rid13">13,15,16</a>].</p><p></p><p class="bulletIndent1">Rarely, the diagnosis of MTC is suggested by the presence of dense calcifications seen on radiographs or imaging of the anterior neck.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Inherited MTC</span><span class="headingEndMark"> — </span>Multiple endocrine neoplasia type 2 (MEN2) is subclassified into two distinct syndromes (MEN2A and MEN2B)  (<a class="graphic graphic_table graphicRef101551" href="/z/d/graphic/101551.html" rel="external">table 2</a>), each of which is transmitted in an autosomal dominant fashion and is associated with MTC. These syndromes result from different mutations in the <em>RET</em> proto-oncogene. In the past, familial MTC (FMTC, an inherited syndrome characterized by the presence of only MTC without hyperparathyroidism or pheochromocytoma) was considered a separate entity but is now considered a variant of MEN2A [<a href="#rid1">1</a>]. Hereditary MTC is typically bilateral and multicentric (see  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Classical MEN2A is associated with MTC, pheochromocytoma, and primary parathyroid hyperplasia. While the penetrance of MTC is nearly 100 percent, there is inter- and intrafamily variability in the specific pattern of the other disease manifestations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MEN2B shares the inherited predisposition to MTC and pheochromocytoma present in classical MEN2A, but does not include hyperparathyroidism. MTC occurs in almost all patients. The tumor develops at an earlier age and may be more aggressive than in MEN2A. Patients typically have a marfanoid habitus (but do not have Marfan syndrome), mucosal neuromas, and intestinal ganglioneuromatosis.</p><p></p><p>In the index case, the clinical presentation and manifestations of MEN2-associated MTC are similar to those of sporadic MTC. The most common presentation is that of a solitary thyroid nodule or cervical lymphadenopathy. Early diagnosis (prior to any clinical manifestations) by screening of "at-risk" family members in MEN2 kindreds is important because MTC is a life-threatening disease that can be cured or prevented by early thyroidectomy. (See  <a class="medical medical_review" href="/z/d/html/7869.html" rel="external">"Classification and genetics of multiple endocrine neoplasia type 2"</a> and  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2", section on 'Screening of family members in MEN2 kindreds'</a> and  <a class="medical medical_review" href="/z/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2"</a>.)</p><p class="headingAnchor" id="H1589349"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of medullary thyroid cancer (MTC) is usually made after fine-needle aspiration (FNA) biopsy in a patient who has a solitary thyroid nodule (or a dominant nodule within a multinodular goiter)  (<a class="graphic graphic_picture graphicRef140062" href="/z/d/graphic/140062.html" rel="external">picture 1</a>). The sensitivity of FNA is 50 to 80 percent, although higher sensitivity can be obtained by the addition of immunocytochemical staining for calcitonin [<a href="#rid17">17,18</a>]. Occasionally, the diagnosis of MTC is made through molecular testing of cytologically indeterminate nodules, as many of the molecular assays include markers for MTC [<a href="#rid19">19</a>]. If the clinical suspicion for MTC is high (eg, patient with diarrhea, flushing, and a thyroid nodule), calcitonin can be measured in the washout of the FNA biopsy needle [<a href="#rid20">20</a>], although this may not be readily available in many commercial laboratories.</p><p>In some cases, the diagnosis of MTC is made after thyroid lobectomy for a suspicious or indeterminate FNA biopsy. Surgical specimens from patients with MTC show spindle-shaped and frequently pleomorphic cells without follicle development because these cells originate from the calcitonin-producing parafollicular C cells of the thyroid  (<a class="graphic graphic_picture graphicRef140063" href="/z/d/graphic/140063.html" rel="external">picture 2</a>).</p><p>The use of serum calcitonin screening to complement ultrasound and FNA in the routine diagnosis of thyroid nodules is controversial in the United States [<a href="#rid21">21</a>]. Measurement of serum calcitonin has not been a part of the routine evaluation of patients with thyroid nodules in the United States. The high frequency of falsely high serum calcitonin values, the inability to confirm the high calcitonin by pentagastrin stimulation in the United States, and the accuracy of FNA biopsy would argue against a change in this recommendation. Further, occasional patients with locoregional metastases or locally invasive MTC will have normal unstimulated serum calcitonin concentrations [<a href="#rid2">2</a>]. In some countries (eg, European countries) where pentagastrin is available, however, serum basal and stimulated calcitonin levels are routinely used in the evaluation of thyroid nodules to facilitate the preoperative diagnosis of MTC. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules", section on 'Serum calcitonin concentration'</a>.)</p><p class="headingAnchor" id="H9087292"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis in a patient presenting with a neck mass is extensive and varies with the age of the patient at presentation. The majority of these masses represent benign thyroid nodules and cysts (see  <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules"</a>). Neck masses that are not of thyroidal origin may be from congenital (ie, vascular anomaly), inflammatory (lymph node enlargement), or other neoplastic (primary or metastatic disease) disorders. The differential diagnosis of a neck mass is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6857.html" rel="external">"Differential diagnosis of a neck mass"</a>.)</p><p>In addition to medullary thyroid cancer (MTC), elevated calcitonin results may also be seen in patients with hypercalcemia, hypergastrinemia, neuroendocrine tumors, renal insufficiency, papillary and follicular thyroid carcinomas, goiter, and chronic autoimmune thyroiditis [<a href="#rid22">22,23</a>]. Furthermore, prolonged treatment with <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a> (greater than two to four months), beta blockers, and glucocorticoids has been associated with hypercalcitoninemia [<a href="#rid24">24</a>]. In addition, the presence of heterophilic antibodies to calcitonin can falsely elevate serum calcitonin levels [<a href="#rid25">25</a>].</p><p>Elevated carcinoembryonic antigen (CEA) levels can also occur in patients with heterophilic antibodies, gastrointestinal tract inflammatory disease, benign lung disease, and nonthyroid malignancies [<a href="#rid1">1</a>]. Cigarette smoking may also elevate CEA.</p><p class="headingAnchor" id="H6"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>For patients diagnosed with medullary thyroid cancer (MTC) on the basis of cytologic evaluation of a thyroid nodule, evaluation should include measurement of serum calcitonin, carcinoembryonic antigen (CEA), ultrasonography of the neck (if not already performed), genetic testing for germline <em>RET</em> mutations, and biochemical evaluation for coexisting tumors, especially pheochromocytoma. Our approach outlined below is largely consistent with National Comprehensive Cancer Network (NCCN) and American Thyroid Association (ATA) Guidelines for Management of Medullary Thyroid Cancer  (<a class="graphic graphic_algorithm graphicRef102747" href="/z/d/graphic/102747.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,26</a>].</p><p class="headingAnchor" id="H1216809"><span class="h2">Serum calcitonin and CEA</span><span class="headingEndMark"> — </span>The serum calcitonin and carcinoembryonic antigen (CEA) concentrations should be measured in patients diagnosed with MTC on the basis of cytologic evaluation of a thyroid nodule. These tests can establish that the tumor is capable of hypersecreting the hormones and, if so, the values can be compared with postoperative values. Postoperatively, results may provide a prognostic factor or indicate biochemical cure [<a href="#rid27">27</a>].</p><p>In a study of 226 patients with MTC (50 percent sporadic MTC, 33 percent multiple endocrine neoplasia [MEN] type 2A [MEN2A], 1 percent MEN type 2B [MEN2B], and 16 percent familial MTC [FMTC]), preoperative serum calcitonin concentrations were significantly correlated with tumor size in both the sporadic and familial cases [<a href="#rid28">28</a>]. In addition, among 45 patients who had a preoperative serum calcitonin concentration of 50 pg/mL or less, 44 had normal concentrations after surgery. In contrast, only 50 of 120 patients with preoperative serum calcitonin concentrations higher than 50 pg/mL had normal concentrations after surgery. In a second study of 224 patients with MTC, 28 of 45 patients (62 percent) without nodal metastases had normal calcitonin postoperatively, while only 18 of 177 (10 percent) of node positive patients had normal postoperative calcitonin levels [<a href="#rid29">29</a>].</p><p>Assessment of calcitonin and CEA doubling times postoperatively provides sensitive markers for progression and aggressiveness of metastatic MTC [<a href="#rid30">30,31</a>]. As an example, postoperative calcitonin doubling time was a prognostic factor for survival in a study of 65 patients followed for 3 to 30 years [<a href="#rid30">30</a>]. Ten-year survival was 8, 37, and 100 percent for doubling times under six months, between six months and two years, and greater than two years, respectively.</p><p class="headingAnchor" id="H7"><span class="h2">Radiologic evaluation</span><span class="headingEndMark"> — </span>MTC can spread by local invasion or metastasis within the neck or distantly [<a href="#rid4">4,6</a>]. When MTC is diagnosed by fine-needle aspiration (FNA) biopsy, ultrasonography of the neck is indicated to look for cervical lymph node involvement.</p><p>For patients with local lymph node metastases on ultrasound or with preoperative serum basal calcitonin &gt;500 pg/mL (indicating high risk of local or distant metastatic disease), additional imaging is required to assess for metastatic disease [<a href="#rid32">32</a>]. In this setting, we suggest cross-sectional imaging including chest computed tomography (CT), neck CT, three-phase contrast-enhanced liver CT or contrast-enhanced liver magnetic resonance imaging (MRI), axial MRI, and bone scintigraphy.</p><p>In patients suspected of having skeletal metastases, MRI may be superior to other imaging modalities [<a href="#rid33">33</a>].</p><p>We do not recommend 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) imaging or somatostatin receptor imaging for routine initial screening for metastatic disease. The sensitivity of FDG-PET scanning for detecting metastatic disease is variable [<a href="#rid34">34,35</a>] but improves with higher calcitonin levels (sensitivity 78 versus 20 percent for basal calcitonin value greater than or less than 1000 pg/mL, respectively) [<a href="#rid36">36</a>]. However, positron emission tomography (PET) scanning with alternative tracers (eg, 18F-dihydroxyphenylalanine [18F-DOPA]) is showing promising results for the detection of recurrent/persistent disease in patients with elevated calcitonin levels and for the selection of patients who may benefit from peptide receptor radionuclide therapy targeting somatostatin receptors, utilizing 68Ga-DOTA peptides (eg, [68Ga]Ga-DOTANOC, [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTATATE) [<a href="#rid37">37-40</a>]. The use of radionuclide imaging with 111-In-octreotide or 99m-Tc-DMSA [<a href="#rid41">41,42</a>] is not recommended for routine initial screening for metastatic disease [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H1589190"><span class="h2">Genetic screening in sporadic MTC</span><span class="headingEndMark"> — </span>We suggest germline <em>RET</em> testing in all patients with newly diagnosed C cell hyperplasia or apparently sporadic MTC. Initial germline testing in patients with C cell hyperplasia or apparently sporadic MTC should include sequencing of exons 10, 11, and 13 through 16 of the <em>RET</em> gene. Sequencing of the remaining exons in the <em>RET</em> gene should be considered in patients with clinical features or family history highly suggestive of hereditary medullary syndromes who demonstrate no mutations in exons 10, 11, or 13 through 16 [<a href="#rid44">44</a>]. While it is possible for clinicians to directly order genetic testing from reference laboratories, we strongly encourage consultation with genetic counselors who are familiar with both the ethical issues and legal informed consent requirements (which can vary significantly in different regions) that are involved in germline testing [<a href="#rid1">1</a>].</p><p>When the index patient is positive for a germline mutation, family members should be offered genetic counseling and genetic screening. (See  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2", section on 'Screening of family members in MEN2 kindreds'</a>.)</p><p>An important question is what proportion of patients with apparently sporadic MTC have unsuspected <strong>germline</strong> mutations in the <em>RET</em> proto-oncogene (the underlying defect in MEN2) and, therefore, have heritable disease. Studies of unselected patients with MTC have found, on average, that approximately 6 to 7 percent (range 1.5 to 24 percent) have germline <em>RET</em> mutations [<a href="#rid45">45-49</a>]. In one report, 35 of 482 patients (7.3 percent) with apparently sporadic MTC had mutations, and in 18 of these 35, gene carriers were identified in relatives [<a href="#rid49">49</a>]. Seventy-five percent of the familial medullary cases had no prior family history.</p><p>A much higher percentage (approximately 60 percent) of patients with sporadic MTC have <strong>somatic</strong> (acquired) mutations in the <em>RET</em> gene within the tumor cells  (<a class="graphic graphic_table graphicRef85653" href="/z/d/graphic/85653.html" rel="external">table 1</a>) [<a href="#rid50">50-53</a>]. These mutations are present only in the tumor cells and are not detected by standard genetic testing, ie, using leukocyte DNA. The presence of somatic <em>RET</em> mutations correlate with lymph node metastases, persistent disease, and lower survival [<a href="#rid54">54</a>]. However, in one study, only mutations in exons 15 and 16 of the <em>RET</em> gene were associated with the worse prognosis, while those in other exons had a more indolent course [<a href="#rid52">52</a>]. Since it is unclear how knowledge of a specific somatic (acquired) <em>RET</em> mutation should impact initial clinical management and follow-up, we do not routinely evaluate primary tumor samples for RET mutational status. However, in patients with symptomatic or structurally progressive disease being considered for a systemic therapy (multitargeted kinase inhibitors or selective RET inhibitors in RET-mutated tumors), we routinely perform somatic mutational profiling of tumor tissue.</p><p class="headingAnchor" id="H8"><span class="h2">Testing for coexisting tumors</span><span class="headingEndMark"> — </span>Most patients require biochemical evaluation for coexisting tumors (particularly pheochromocytoma and hyperparathyroidism) prior to thyroidectomy. Even when genetic screening is performed preoperatively, the results are rarely known prior to surgery.</p><p>For patients with unknown <em>RET</em> mutational status and for patients who have a germline <em>RET</em> mutation, we measure:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium (to rule out hyperparathyroidism requiring concomitant surgical intervention).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma fractionated metanephrines (as the initial screen for pheochromocytoma).</p><p></p><p class="bulletIndent1">Normal plasma fractionated metanephrines values exclude a symptomatic catecholamine-secreting neoplasm, but mildly elevated values of normetanephrine could be falsely positive, in which case additional evaluations including 24-hour urinary fractionated metanephrines, catecholamines, and adrenal imaging may be required to effectively rule in or rule out pheochromocytoma prior to surgery. Adrenal imaging should not be performed unless there is biochemical evidence suggesting a possible pheochromocytoma. (See  <a class="medical medical_review" href="/z/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a>.)</p><p></p><p>In a patient with negative <em>RET</em> proto-oncogene testing and no family history of MEN2 syndrome, biochemical testing for coexisting tumors is typically not required.</p><p class="headingAnchor" id="H10"><span class="h1">STAGING</span></p><p class="headingAnchor" id="H1664807238"><span class="h2">TNM staging</span><span class="headingEndMark"> — </span>The pathological tumor, node, metastasis (pTNM) criteria for clinicopathologic tumor staging (eighth edition) adopted by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) are based upon tumor size and the presence or absence of extrathyroidal invasion, local and regional nodal metastases, and distant metastases  (<a class="graphic graphic_table graphicRef110636" href="/z/d/graphic/110636.html" rel="external">table 3</a>) [<a href="#rid55">55</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage I</strong> – Medullary thyroid cancers (MTCs) that are less than 2 cm in diameter without evidence of disease outside of the thyroid gland</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage II</strong> – Tumors &gt;2 cm confined to the thyroid or tumors of any size without lymph node metastasis that demonstrate gross extrathyroidal extension invading only the strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage III</strong> – Tumors of any size demonstrating metastatic lymph node involvement in the central neck (levels VI or VII; pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal lymph nodes) with or without gross invasion into the strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IV</strong> – Any distant metastases, or lymph node involvement outside of the central neck (level VI/VII), or gross invasion into other structures of the neck (beyond just strap muscle involvement)</p><p></p><p>One study evaluated the prognostic significance of a previous TNM staging scheme in patients with MTC, most of whom were treated by total thyroidectomy and then followed for a median of four years [<a href="#rid3">3</a>]. Although the follow-up was short, mortality due to MTC was 0 percent in patients with stage I disease, 13 percent in stage II, 56 percent in stage III, and 100 percent in stage IV [<a href="#rid3">3</a>]. A subsequent analysis of MTC patients using the National Cancer Database and the SEER (Surveillance, Epidemiology, and End Results) data set demonstrated that the seventh and eighth editions of the AJCC staging system were associated with five-year overall survival rates of 95 percent in stage I, 91 percent in stage II, 89 percent in stage III, and 68 percent in stage IV. Furthermore, disease-specific survival rates were 100 percent in stage I, 99 percent in stage II, 97 percent in stage III, and 82 percent in stage IV [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H4148301804"><span class="h2">Dynamic risk stratification</span><span class="headingEndMark"> — </span>Using the same concepts that were initially developed for differentiated thyroid cancer (see  <a class="medical medical_review" href="/z/d/html/7839.html" rel="external">"Differentiated thyroid cancer: Clinicopathologic staging", section on 'Dynamic risk stratification'</a>), dynamic risk stratification for MTC allows clinicians to modify initial AJCC staging risk estimates over time based on the biological behavior the tumor and the response to therapy in individual patients [<a href="#rid57">57,58</a>]. For application in MTC, the definitions of the response to therapy categories needed to be modified to utilize calcitonin and carcinoembryonic antigen (CEA) as tumor markers (rather than thyroglobulin). At each follow-up visit, patients are classified as having one of the following clinical outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excellent response</strong> – An undetectable calcitonin and normal-range CEA in the absence of structurally identifiable disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biochemical incomplete response</strong> – A detectable calcitonin or elevated CEA in the absence of structurally identifiable disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Structural incomplete response</strong> – The presence of recurrent or persistent structurally identifiable disease</p><p></p><p>In three retrospective studies examining MTC patients with a median of five to seven years of follow-up, an excellent response to therapy was associated with a structural disease recurrence rate of 1 to 4 percent and a biochemical recurrence rate of 11 to 15 percent, with a disease-specific mortality of &lt;3 percent [<a href="#rid59">59-61</a>]. However, patients with a biochemical incomplete response demonstrated a disease-specific mortality of 11 percent with the vast majority demonstrating persistent biochemical evidence of disease (51 to 53 percent) or structural evidence of disease (32 to 37 percent). The poorest outcomes were seen in those patients with a structural incomplete response to initial therapy with disease-specific mortality rates of 38 to 56 percent.</p><p>As noted above, the calcitonin and CEA doubling times can also provide meaningful insights into prognosis and expected course of disease progression that can further refine these response to therapy assessments [<a href="#rid30">30,31</a>]. (See <a class="local">'Serum calcitonin and CEA'</a> above.)</p><p class="headingAnchor" id="H2001847736"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117633.html" rel="external">"Society guideline links: Medullary thyroid cancer"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular or C cells of the thyroid gland; it accounts for approximately 1 to 2 percent of thyroid carcinomas. The production of calcitonin is a characteristic feature of this tumor. Most cases are sporadic  (<a class="graphic graphic_table graphicRef85653" href="/z/d/graphic/85653.html" rel="external">table 1</a>). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1">A solitary thyroid nodule is the most common presentation of sporadic MTC (in 75 to 95 percent of patients). In most patients, the disease has already metastasized at the time of diagnosis. Basal serum calcitonin concentrations usually correlate with tumor mass but also reflect tumor differentiation, and they are almost always high in patients with a palpable tumor. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of sporadic MTC is usually made after fine-needle aspiration (FNA) biopsy in a patient who has a solitary thyroid nodule (or a dominant nodule within a multinodular goiter)  (<a class="graphic graphic_picture graphicRef140062" href="/z/d/graphic/140062.html" rel="external">picture 1</a>). The sensitivity of FNA is improved by the addition of immunohistochemical staining for calcitonin. The routine use of serum calcitonin screening to complement FNA in the routine diagnosis of thyroid nodules is controversial in the United States. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/7890.html" rel="external">"Diagnostic approach to and treatment of thyroid nodules", section on 'Serum calcitonin concentration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – For patients diagnosed with MTC on the basis of cytologic evaluation of a thyroid nodule, evaluation includes biochemical, radiologic, and genetic testing  (<a class="graphic graphic_algorithm graphicRef102747" href="/z/d/graphic/102747.html" rel="external">algorithm 1</a>). (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serum calcitonin and CEA</strong> – Initial biochemical testing should include measurement of serum calcitonin and carcinoembryonic antigen (CEA). These tests can establish that the tumor is capable of hypersecreting the hormones and, if so, the values can be compared with postoperative values. Postoperatively, results may provide a prognostic factor or indicate biochemical cure. (See <a class="local">'Serum calcitonin and CEA'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Radiologic evaluation</strong> – When MTC is diagnosed by fine-needle aspiration (FNA) biopsy, ultrasonography of the neck is indicated (if not already performed) to look for cervical lymph node involvement. For patients with local lymph node metastases on ultrasound or with preoperative serum basal calcitonin &gt;500 pg/mL (indicating high risk of local or distant metastatic disease), additional imaging is required to assess for metastatic disease. (See <a class="local">'Radiologic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetic testing for germline</strong> <strong><em>RET</em></strong><strong> mutations</strong> – Some patients with apparently sporadic MTC have unsuspected germline <em>RET</em> mutations (the underlying defect in multiple endocrine neoplasia type 2 [MEN2]) and, therefore, heritable disease. We suggest germline <em>RET</em> testing to all patients with newly diagnosed C cell hyperplasia or apparently sporadic MTC. (See <a class="local">'Genetic screening in sporadic MTC'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Testing for coexisting tumors</strong> – Given the possibility that any patient with MTC may have MEN2, if results of germline <em>RET</em> testing are unknown (or positive), preoperative testing must also include measurement of serum calcium (to rule out hyperparathyroidism requiring concomitant surgical intervention) and testing for pheochromocytoma. We suggest plasma fractionated metanephrines as the initial screen for pheochromocytoma. (See <a class="local">'Testing for coexisting tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging </strong>– Initial staging is based upon tumor size and the presence or absence of extrathyroidal invasion, local and regional nodal metastases, and distant metastases  (<a class="graphic graphic_table graphicRef110636" href="/z/d/graphic/110636.html" rel="external">table 3</a>). Dynamic risk stratification for MTC allows clinicians to modify initial staging risk estimates over time based on the biological behavior the tumor and the response to therapy in individual patients. (See <a class="local">'Staging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of MTC is discussed in detail separately. MEN2 is also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2190.html" rel="external">"Medullary thyroid cancer: Surgical treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a> and  <a class="medical medical_review" href="/z/d/html/7869.html" rel="external">"Classification and genetics of multiple endocrine neoplasia type 2"</a> and  <a class="medical medical_review" href="/z/d/html/7866.html" rel="external">"Approach to therapy in multiple endocrine neoplasia type 2"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567.</a></li><li><a class="nounderline abstract_t">Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984; 63:319.</a></li><li><a class="nounderline abstract_t">Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996; 77:1556.</a></li><li class="breakAll">Gagel RF, Hoff AO, Cote GJ. Medullary thyroid carcinoma. In: Werner &amp; Ingbar's The Thyroid, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.967.</li><li><a class="nounderline abstract_t">Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88:1139.</a></li><li><a class="nounderline abstract_t">Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010; 22:475.</a></li><li><a class="nounderline abstract_t">Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 2007; 31:1960.</a></li><li><a class="nounderline abstract_t">Scheuba C, Kaserer K, Bieglmayer C, et al. Medullary thyroid microcarcinoma recommendations for treatment - a single-center experience. Surgery 2007; 142:1003.</a></li><li><a class="nounderline abstract_t">Machens A, Dralle H. Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. Eur J Endocrinol 2016; 175:219.</a></li><li><a class="nounderline abstract_t">Kwon H, Kim WG, Sung TY, et al. Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma. J Surg Oncol 2016; 113:152.</a></li><li><a class="nounderline abstract_t">Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg 2007; 142:289.</a></li><li><a class="nounderline abstract_t">Busnardo B, Girelli ME, Simioni N, et al. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984; 53:278.</a></li><li><a class="nounderline abstract_t">Trimboli P, Nasrollah N, Amendola S, et al. Should we use ultrasound features associated with papillary thyroid cancer in diagnosing medullary thyroid cancer? Endocr J 2012; 59:503.</a></li><li><a class="nounderline abstract_t">Choi N, Moon WJ, Lee JH, et al. Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results. Acta Radiol 2011; 52:312.</a></li><li><a class="nounderline abstract_t">Lee S, Shin JH, Han BK, Ko EY. Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. AJR Am J Roentgenol 2010; 194:1090.</a></li><li><a class="nounderline abstract_t">Kim SH, Kim BS, Jung SL, et al. Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol 2009; 10:101.</a></li><li><a class="nounderline abstract_t">Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 2005; 91:56.</a></li><li><a class="nounderline abstract_t">Bhanot P, Yang J, Schnadig VJ, Logroño R. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature. Diagn Cytopathol 2007; 35:285.</a></li><li><a class="nounderline abstract_t">Nikiforova MN, Mercurio S, Wald AI, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 2018; 124:1682.</a></li><li><a class="nounderline abstract_t">Kudo T, Miyauchi A, Ito Y, et al. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid 2007; 17:635.</a></li><li><a class="nounderline abstract_t">Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist 2011; 16:49.</a></li><li><a class="nounderline abstract_t">Toledo SP, Lourenço DM Jr, Santos MA, et al. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo) 2009; 64:699.</a></li><li><a class="nounderline abstract_t">Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 2005; 142:926.</a></li><li><a class="nounderline abstract_t">Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest 2006; 29:771.</a></li><li><a class="nounderline abstract_t">Preissner CM, Dodge LA, O'Kane DJ, et al. Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. Clin Chem 2005; 51:208.</a></li><li class="breakAll">http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on August 20, 2012).</li><li><a class="nounderline abstract_t">Machens A, Hauptmann S, Dralle H. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? J Clin Endocrinol Metab 2008; 93:2234.</a></li><li><a class="nounderline abstract_t">Cohen R, Campos JM, Salaün C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab 2000; 85:919.</a></li><li><a class="nounderline abstract_t">Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005; 90:2029.</a></li><li><a class="nounderline abstract_t">Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005; 90:6077.</a></li><li><a class="nounderline abstract_t">Laure Giraudet A, Al Ghulzan A, Aupérin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008; 158:239.</a></li><li><a class="nounderline abstract_t">Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2655.</a></li><li><a class="nounderline abstract_t">Mirallié E, Vuillez JP, Bardet S, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 2005; 90:779.</a></li><li><a class="nounderline abstract_t">Oudoux A, Salaun PY, Bournaud C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 2007; 92:4590.</a></li><li><a class="nounderline abstract_t">Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007; 92:4185.</a></li><li><a class="nounderline abstract_t">Ong SC, Schöder H, Patel SG, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007; 48:501.</a></li><li><a class="nounderline abstract_t">Asa S, Sonmezoglu K, Uslu-Besli L, et al. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT. Ann Nucl Med 2021; 35:900.</a></li><li><a class="nounderline abstract_t">Giovanella L, Deandreis D, Vrachimis A, et al. Molecular Imaging and Theragnostics of Thyroid Cancers. Cancers (Basel) 2022; 14.</a></li><li><a class="nounderline abstract_t">Klain M, Hadoux J, Nappi C, et al. Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives. Endocrine 2022; 75:330.</a></li><li><a class="nounderline abstract_t">Castinetti F, Taïeb D. Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal? Thyroid 2021; 31:151.</a></li><li><a class="nounderline abstract_t">Berná L, Cabezas R, Mora J, et al. 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 1995; 144:339.</a></li><li><a class="nounderline abstract_t">Udelsman R, Ball D, Baylin SB, et al. Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid. Surgery 1993; 114:1083.</a></li><li><a class="nounderline abstract_t">American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565.</a></li><li><a class="nounderline abstract_t">Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med 2011; 13:755.</a></li><li><a class="nounderline abstract_t">Eng C, Mulligan LM, Smith DP, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995; 43:123.</a></li><li><a class="nounderline abstract_t">Zedenius J, Wallin G, Hamberger B, et al. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Hum Mol Genet 1994; 3:1259.</a></li><li><a class="nounderline abstract_t">Wohllk N, Cote GJ, Bugalho MM, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:3740.</a></li><li><a class="nounderline abstract_t">Decker RA, Peacock ML, Borst MJ, et al. Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete? Surgery 1995; 118:257.</a></li><li><a class="nounderline abstract_t">Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007; 92:4725.</a></li><li><a class="nounderline abstract_t">Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996; 81:1619.</a></li><li><a class="nounderline abstract_t">Marsh DJ, Learoyd DL, Andrew SD, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1996; 44:249.</a></li><li><a class="nounderline abstract_t">Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 2009; 100:1777.</a></li><li><a class="nounderline abstract_t">Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011; 96:E863.</a></li><li><a class="nounderline abstract_t">Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008; 93:682.</a></li><li class="breakAll">Rosen JE, Lloyd RV, Brierly JD, et al. Thyroid - Medullary. In: AJCC Cancer Staging Manual, 8th, Amid AB (Ed), Springer, New York 2017. p.891. Corrected at 4th printing, 2018.</li><li><a class="nounderline abstract_t">Adam MA, Thomas S, Roman SA, et al. Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer. JAMA Surg 2017; 152:869.</a></li><li><a class="nounderline abstract_t">Tuttle RM, Ganly I. Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging. Oral Oncol 2013; 49:695.</a></li><li><a class="nounderline abstract_t">Yang JH, Lindsey SC, Camacho CP, et al. Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer. Clin Endocrinol (Oxf) 2015; 83:938.</a></li><li><a class="nounderline abstract_t">Lindsey SC, Ganly I, Palmer F, Tuttle RM. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid 2015; 25:242.</a></li><li><a class="nounderline abstract_t">Kwon H, Kim WG, Jeon MJ, et al. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy. Endocrine 2016; 53:174.</a></li><li><a class="nounderline abstract_t">Fanget F, Demarchi MS, Maillard L, et al. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels. Br J Surg 2021; 108:1064.</a></li></ol></div><div id="topicVersionRevision">Topic 7848 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25810047" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6503683" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608543" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608543" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699905" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20627492" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17665245" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18063088" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Medullary thyroid microcarcinoma recommendations for treatment - a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27334331" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26799259" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17372055" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6690009" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22447142" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Should we use ultrasound features associated with papillary thyroid cancer in diagnosing medullary thyroid cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21498368" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308516" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19270854" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15999359" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17427218" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29345728" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17696833" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21212427" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19606248" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15941700" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Continuing controversies in the management of thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114906" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term effects of elevated gastrin levels on calcitonin secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613712" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613712" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18364379" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690910" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15634717" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16091497" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230832" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20339026" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Biomarker-based risk stratification for previously untreated medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15572422" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17878252" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17726071" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401085" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33993425" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35267580" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Molecular Imaging and Theragnostics of Thyroid Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34748168" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33191866" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7706986" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256211" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19469690" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Medullary thyroid cancer: management guidelines of the American Thyroid Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21552134" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Multiple endocrine neoplasia type 2: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7641404" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7987299" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855832" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7638742" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17895320" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636377" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8729519" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19401695" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21325462" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18073307" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18073307" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28636692" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23601563" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25376110" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25338223" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Response to initial therapy predicts clinical outcomes in medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26754662" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33899100" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
